CClinicalTrials.gg
Status unknownNCT04126122Updated Oct 15, 2019

Maternal and Neonatal Outcome in Severe Preeclampsia

An observational study in Pre-Eclampsia, sponsored by Aljazeera Hospital. Status unknown at 1 site in Egypt. Open to female participants aged 20 Years to 42 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-10-15.

Sponsored by Aljazeera Hospital · Observational

The sponsor has not verified this record recently (last verified Oct 2019), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
20 Years to 42 Years
Sex
Female
01

Study summary

In normal pregnancy the spiral arteries in the placental bed are invaded by trophoblast, which becomes incorporated into the vessel wall and replaces the endothelium, muscular layer and neural tissue

Read the detailed description

Preeclampsia is considered severe if one or more of the following:

  1. Blood pressure of 160mmHg systolic or high or 110mmHg diastolic or high on two occasions at least 6 hours a part while the patient on bed rest.
  2. Proteinuria of 0.3gm. or high in 24 hours urine specimen or +1 or great on two random urine samples collected at least 4 hours apart.
  3. Oliguria of less than 500ml in 24 hours.
  4. Cerebral or visual disturbance.
  5. Pulmonary edema or cyanosis.
02

Conditions studied

  • Pre-Eclampsia
03

In context

Eclampsia

328 studies on the registry are indexed under Eclampsia; 48 are open to participants now.

This study's planned enrollment of 100 is below the median of 158 across 146 observational studies indexed under Eclampsia.

Browse Eclampsia studies →

Lead sponsor

Aljazeera Hospital is the lead sponsor of 63 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 42 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

pregnant ladies with preeclampsia

Inclusion criteria

    • All women with severe preeclampsia

Exclusion criteria

Exclusion Criteria:

    • History of epilepsy.

      • Patients with chronic hypertension.
      • Patients with renal disease.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No

Interventions

  • Diagnostic testUltrasonography to assess fetus and mother

    to assess fetal growth and maternal outcome

06

What researchers measure

Primary outcomes

  1. The number of women who will develop adverse outcome

    The women with preeclampsia who will develop eclampsia or pulmonaryb edema

    Time frame: within 5 months

07

Study locations

1 of 1 sites recruiting
  • Aljazeera( Al Gazeera) hospital
    Giza, Egypt
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 15, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04126122
Lead sponsor
Aljazeera Hospital
Collaborators
Cairo University
Responsible party
Mahmoud Alalfy (Researcher , lecturer ,Obstetrics and Gynecology , National Research Centre, Aljazeera Hospital) — Principal investigator
First posted
Oct 15, 2019
Start date
Feb 10, 2019
Primary completion
Jan 10, 2020 (estimated)
Completion
Feb 1, 2020 (estimated)
Last update
Oct 15, 2019

Study contacts

Mahmoud Alalfy, PhD
Contact
mahmoudalalfy@ymail.com
01002611058

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion